Alcor to Release Ted Williams' Document of Gift

PHOENIX, Sept. 17, 2004 -- Joe Waynick, chief executive officer for Alcor Life Extension Foundation Inc., announced today that the company will comply with a court order to release the document of gift for Ted Williams.

"We are ready, willing and able to comply with court rulings regarding the release of the document of gift of any Alcor patient, if ordered through proper legal channels," Waynick said. "In order to expedite the court's order, Alcor has submitted a judgment to the court in favor of the plaintiffs which will allow them access to the document of gift."

Waynick continued, "Alcor is dedicated to preserving the confidentiality of our patients if they so request, or if requested by donating family members, for as long and as completely as possible; however, we also have a responsibility to obey court orders."

Maricopa County Superior Court Judge Thomas Dunevant III recently ordered Alcor to present a document of gift for Ted Williams to nephews Ted and Sam Williams.

Waynick noted that Alcor was merely an ancillary third party in the legal dispute among family members over the disposition of Williams' body and that the Foundation was not accused of any wrongdoing. "Alcor was entitled to obtain a court determination concerning the requirements of the Arizona Anatomical Gift Act before releasing the document of gift," said Waynick. "The court order provides the necessary legal directive to release the document as required under this Act."

[Added note from Alcor News for September 22: Alcor plans to release the document as soon as a final judgment is signed by the court.]


About Alcor Life Extension Inc.

The Alcor Life Extension Foundation, a nonprofit organization founded in 1972, is the world leader in cryonics, and cryonics research and technology. Cryonics is the science of using ultra-cold temperatures to suspend and preserve human life. The intent is that technologically advanced scientific procedures will one day be available to revive cryopreserved humans and restore them to good health.

The promise of cryopreservation has taken a quantum leap forward with the ongoing development of molecular nanotechnology and the introduction of vitrification to Alcor's protocols.

One use of nanotechnology is the expectation that cell-sized machines will be developed to repair damage or cure disease at the cellular level, including any potential damage that results from the cryopreservation processes.

Alcor performed its first human cryopreservation in 1976. Since then, Alcor has engaged in long-term patient care as well as cryopreservation procedures. Among Alcor's scientific achievements is the use of advanced cryoprotectant formulas capable of achieving ice-free preservation, known as vitrification.

Today, Alcor is the only full-service cryonics organization in existence. Alcor has more than 680 members from around the world and 65 patients in cryostasis. For more information about Alcor and cryonics, visit http://www.alcor.org.

###